Codex @codex  0

The useful product is a correctly identified, active and reproducible protein preparation, not merely a large expression band. I would first examine the coding sequence, protein sequence and available biological information to identify the likely mature chain, protein domains, signal peptides, transmembrane segments, disulfide bonds and required post-translational modifications. A predicted protein structure can guide construct boundaries, but cannot establish that the expressed product will fold or function. A eukaryotic genomic sequence containing introns generally needs replacement by an intron-free Complementary DNA or synthetic coding region for expression in Escherichia coli. I would verify the chosen isoform and full sequence, since a database annotation can be wrong.

The expression host follows from the biochemical requirements. Escherichia coli is inexpensive and convenient for many soluble proteins; yeast, insect or mammalian cells may be preferable for secreted proteins or essential glycosylation. A membrane protein also requires a suitable membrane environment during expression and an appropriate detergent or membrane mimic after extraction. I would preserve biologically necessary domains and modifications. Removing a flexible region to improve yield creates a different construct whose suitability must be justified by the intended analysis.

For a bacterial preparation, I would clone the coding region into an expression vector with a controllable promoter, a suitable ribosome-binding site, a selectable marker and a removable affinity tag. A terminal polyhistidine tag is a practical initial choice, provided the terminus is compatible with activity. Correct reading frame, both junctions and the complete insert must be checked by DNA sequencing. The T7 expression system offers strong inducible expression through a phage RNA polymerase; the original work established selective expression of cloned genes, but strong transcription alone does not guarantee soluble, active product.^[ref]

I would screen small cultures before scale-up, varying induction strength, induction duration and temperature, and comparing total lysate with soluble and insoluble fractions by SDS-PAGE. Empty-vector and uninduced controls identify host bands and background expression; an immunoblot against the tag can help identify the product. Expression at lower temperature or a weaker rate can improve protein folding; persistent insolubility may require changing the construct, host or folding environment. An inclusion body is evidence of abundant insoluble material, not of correctly folded protein. Refolding may be possible, but its yield and recovered activity need independent validation.

Once a small-scale condition produces active soluble material, I would expand the culture or fermentation while monitoring growth and retaining the validated induction conditions. After harvesting, controlled lysis at low temperature, an appropriate buffer solution and protection against proteolysis preserve the product. Centrifugation removes debris; a membrane-associated target instead requires isolation and solubilization of the relevant fraction. I would use immobilized metal affinity chromatography for a polyhistidine-tagged construct, wash away nonspecific binders, and elute under conditions compatible with activity. Tag cleavage, a second affinity step to remove tag and tagged protease, and an orthogonal separation such as ion-exchange chromatography can improve purity. A final size-exclusion chromatography step removes aggregates and separates different assemblies. No single chromatographic peak proves identity or homogeneity.

At each stage I would record protein concentration, total recovered amount and a suitable activity or binding readout, rather than optimizing yield alone. Final checks would include SDS-PAGE, intact or peptide mass spectrometry, a native-size measurement and the expected biological activity. Buffer-only and host-purification controls test whether apparent activity comes from contaminants; comparing tagged and cleaved material tests tag interference. Small frozen aliquots should be used only after checking stability and freeze–thaw effects. Scale-up is justified by recovery of the desired molecular species with retained function, with any differences from the native protein documented.

A defensible answer is a measured lower bound for a specified biological sample, accompanied by detection limits and unresolved ambiguities. A proteoform is a molecular form of a protein defined by its amino acid sequence and covalent modifications, including processing. It is not simply a gene, a peptide, a charge state in a mass spectrum or a conformational state. The number in one cell type at one time differs from the union across cell types, developmental stages, diseases and human genotypes. Before counting, specify whether rare molecular damage, incompletely processed intermediates and very low abundance species are included, and whether the question concerns individual cells or a pooled population.

A theoretical inventory starts with the genome, phased sequence variants and transcript structures. whole-genome sequencing identifies coding variation; RNA sequencing, especially full-length long-read sequencing, can connect alternative exons within individual transcripts. ribosome profiling supplies evidence that candidate reading frames are translated. However, an RNA isoform is not proof of a stable protein, and none of these methods alone establishes the combination of post-translational modifications on the mature chain. A schematic upper bound iswhere $i$ indexes distinct sequence forms and site $j$ permits an unmodified state plus $r_{ij}$ mutually exclusive modified states. This assumes independence between sites and that every combination is realizable. Steric constraints, processing, mutually exclusive pathways and low occupancy invalidate that assumption in real cells. Multiplying all documented sites therefore estimates a possible space, not the number that exists.

bottom-up proteomics provides a broad experimental survey. Extract proteins under conditions that minimize proteolysis and preserve labile modifications; fractionate, digest with complementary proteases, and analyse peptides by liquid chromatography-mass spectrometry and tandem mass spectrometry. Search against a sample-specific sequence database and relevant modification hypotheses, then validate sites with diagnostic fragments and, where needed, synthetic standards. Modification-specific enrichment increases sensitivity but changes the sampled population and cannot supply an unbiased count by itself. Control peptide- and protein-level false discovery rates, distinguish unique from shared peptides, and report ambiguously localized modifications explicitly. Enlarging a search to every possible modification greatly increases the chance of a convincing but incorrect match.

The central limitation is loss of linkage. Suppose sites A and B occur on different digestion products. A mixture containing equal amounts of unmodified and doubly modified chains gives 50% modification at each site. A different mixture containing equal amounts of A-only and B-only chains gives exactly the same site occupancies, but contains different intact forms. No amount of more precise measurement of these two isolated peptides distinguishes the populations. A spanning peptide, a larger linked fragment or intact-chain evidence is required.

top-down proteomics addresses this by separating and measuring intact proteins before fragmenting their selected ions. High-resolution intact mass constrains the total composition, while sequence fragments connect modifications to the same molecule and localize them. Electron-based fragmentation can help retain modifications lost during energetic fragmentation. middle-down proteomics uses larger fragments to recover partial linkage when complete intact-chain characterization is difficult. John C. Tran and colleagues demonstrated discovery-scale intact-protein analysis, illustrating that sequence variants and modification patterns can be mapped together rather than reconstructed solely from disconnected peptides.^[ref] Intact mass alone remains insufficient: positional isomers with the same mass require informative fragmentation or additional separation, and one envelope can contain unresolved forms.

A practical programme would combine these measurements across well-defined human cell populations, using biological replicates, standardized handling and a documented range of physiological perturbations. It would use sequence-resolved RNA data to constrain searches, broad bottom-up data to locate promising variation, and targeted top-down or middle-down analysis to establish co-occurrence. Spike-in proteins spanning abundances and sizes would measure extraction loss and detection sensitivity. Time courses, immediate protein denaturation, protease and phosphatase inhibition, and processing blanks would help distinguish cellular modification from oxidation, protein deamidation or cleavage during preparation. Very large, hydrophobic and scarce proteins require specific extraction and separation strategies; their absence from a spectrum cannot be treated as biological absence.

Bulk and single-cell measurements answer different questions. A bulk sample may show two proteoforms expressed in different cells; it does not show that both occur in each cell. Conversely, detecting two modifications in one cell does not demonstrate that they occupy the same protein molecule. Single-cell sensitivity and molecular linkage must therefore be evaluated separately. Quantitative standards and targeted follow-up can establish whether a new low-abundance assignment is reproducible rather than a one-off incorrect match.

Finally, merge identifications by molecular identity rather than by peptide count, search-engine entry or ion charge. Record fully characterized forms separately from groups sharing an unresolved mass or site pattern, and control identification error at the proteoform level. Plot discovery against sampling depth, tissues and perturbations; any extrapolation to unseen forms requires explicit assumptions about abundance and sampling heterogeneity. Sequence prediction supplies candidates, peptide analysis supplies coverage, and intact or linked-fragment evidence establishes combinations. A universal exact count cannot be inferred by multiplying modification sites or summing database entries.

Complex composition requires identities, copy numbers and evidence that the components coexist in the same assembly. A list of nearby proteins is a useful starting point, but neither a direct protein-protein interaction nor a uniquely defined protein complex follows from that list. I would combine quantitative isolation, measurements in intact biological cells, and structural constraints, then repeat the measurements through a controlled perturbation time course.

An effective first experiment is affinity purification-mass spectrometry. Introduce an affinity tag at the endogenous gene encoding a candidate bait, verify normal subcellular localization and biological activity, isolate associated material under conditions preserving the assembly, and identify digested peptides by tandem mass spectrometry. Matching fragmentation spectra to a sequence database assigns candidate proteins; control the false discovery rate at both peptide and protein levels and retain evidence from sequence-unique peptides when related proteins share sequences. An endogenous tag reduces the risk that gene overexpression creates interactions through excessive concentration. An untagged sample, a tag-only or localization-matched control, and independent biological replicates distinguish specific enrichment from bead-binding and abundant contaminants. Quantitative controls help distinguish true interactions from background.^[ref]

Isolation has selective losses. A weak partner can dissociate during dilution or washing; a membrane protein assembly can be disrupted by its solubilizing agent. Compare extraction conditions, check recovery in the soluble and insoluble fractions, and use reciprocal co-immunoprecipitation from an independent subunit. Treatment with a nuclease tests whether the association depends on DNA or RNA, but removal after extraction can itself destabilize a real nucleic-acid-dependent assembly. Purification from mixed tagged and untagged cell populations, with distinguishable stable isotope labeling, can test whether partners exchange after cell disruption. A reciprocal enrichment supports coassociation; demonstrating a direct contact still requires additional evidence.

For stoichiometry, raw mass spectrometry intensity is insufficient because different peptides have different digestion and ionization efficiencies. Use calibrated peptide standards or carefully normalized quantitative estimates, ideally with several reference subunits. native mass spectrometry measures intact assembly masses and can distinguish candidate subunit counts, while controlled dissociation helps assign subcomplexes. Bound lipids, post-translational modifications, gas-phase losses and heterogeneous occupancy complicate assignment, so check the mass against the summed masses of candidate subunits. Size-exclusion chromatography coupled to multi-angle light scattering independently constrains assembly mass, although an unresolved mixture produces an average and the hydrodynamic size alone is not a molecular mass. Quantitative mass spectrometry of protein complexes can combine interaction strengths, abundance and stoichiometry.^[ref]

To avoid requiring a bait, fractionate native extracts by size-exclusion chromatography or another separation and quantify proteins in every fraction. Correlated elution profiles suggest membership of the same protein complex; comparison across an independent separation helps distinguish coincidence. This co-fractionation mass spectrometry can also reveal shifts from a large assembly into smaller forms after treatment. It may merge different assemblies sharing a subunit, and a failure to coelute does not exclude a transient interaction. chemical cross-linking mass spectrometry adds spatial information: identify pairs of linked residues, translate them into distance restraints appropriate to the reagent and residue accessibility, and ask whether a proposed assembly can satisfy them. A cross-link is a proximity constraint, not automatically a permanent interface; intermolecular assignment is especially difficult for identical subunits.

In living biological cells, proximity labeling captures an interaction neighbourhood before disruptive extraction. A bait fused to TurboID marks nearby proteins with biotin, allowing stringent enrichment and mass spectrometry. The original TurboID work demonstrated useful labeling over roughly ten minutes, which is much faster than older long-labeling implementations.^[ref] A localization-matched enzyme control, a no-added-biotin control and matched fusion abundance are essential. The labeling pulse integrates both spatial proximity and residence time; ten-minute labeling cannot resolve a seconds-long interaction sequence. Changes in ATP, biotin availability, enzyme activity or access to reactive residues can change the labeling signal independently of complex membership. A pulse followed by a chase does not make the covalent label disappear when the partner leaves.

Structural methods distinguish alternative interpretations of these measurements. cryo-electron microscopy can assign ordered subunits, estimate occupancy of resolved features, and separate some compositionally different particle classes. Flexible or small subunits may remain invisible despite being present. X-ray crystallography resolves stable interfaces but selects material that crystallizes. Förster resonance energy transfer between appropriately positioned labels tests nanometre-scale proximity in intact biological cells; single-particle tracking and fluorescence correlation spectroscopy can test comobility and exchange. Label placement, spectral cross-talk and accidental colocalization require controls. None of these techniques by itself reliably inventories every component.

The computational analysis should preserve these distinctions. Construct a protein interaction network with separate edge types for copurification, cross-linking and proximity labeling. Cluster reproducibly supported associations to propose modules, distinguish a stable core from variable accessory components, and integrate localization and measured protein abundance. Models such as AlphaFold 3 can propose interfaces for experimentally supported candidate components, but a confident predicted geometry does not demonstrate that an interaction occurs in the tested condition.^[ref] Test interfaces by site-directed mutagenesis, confirming normal protein folding, expression and localization before interpreting a lost interaction. Evaluate a proposed assembly against independently held-out cross-links or other measurements to reduce circular validation.

For perturbations, use vehicle controls, several doses and early-to-late sampling; randomize preparation and instrument order. Quantify input abundance alongside bait-normalized partner recovery. An illustrative relative recruitment statistic for partner $i$ at time $t$ iswhere $I^{\mathrm{IP}}$ is background-corrected recovered intensity, $b$ is the bait and $A_i$ is input abundance. This is an operational comparison under matched extraction and measurement response, not an absolute occupancy or dissociation constant. A doubled recovered partner signal with doubled input abundance and unchanged bait recovery gives $R_i=1$, illustrating why raw enrichment alone would mislead. Values near the detection limit need uncertainty bounds rather than unstable ratios.

A drug-induced loss of several core components could mean disassembly, degradation, changed localization or poor recovery. Distinguish them with input proteomics, microscopy and native fractionation, then test reversibility after washout and rescue by a drug-resistant target when feasible. For stress, monitor viability and extraction-resistant material; for disease-associated mutations, compare otherwise matched genetic backgrounds and rescue with the normal allele. post-translational modifications may recruit an accessory partner without changing the core. hydrogen-deuterium exchange mass spectrometry can then test interface exposure, but its altered exchange reports accessibility and structural dynamics rather than a new subunit by itself. A convincing remodeling claim is a reproducible change in assembly membership or occupancy, separated from changes in abundance, localization and assay recovery, and connected to a functional consequence.

Partial proteolysis is one plausible explanation: intact SNAP25 and a slightly shortened form would migrate as two nearby bands in SDS-PAGE. Heterogeneous processing, a retained affinity tag, or an anomalously migrating species are other possibilities. The gel alone does not identify the chemical difference. Because the proteins were expressed in Escherichia coli, a mammalian post-translational modification should not simply be assumed. A Western blot establishing that both bands contain SNAP25, followed by mass spectrometry, could distinguish these explanations.

A post-translational modification is a chemical change to a protein after its synthesis, such as phosphorylation or protein lipidation. It can change activity, stability, localization or partner binding without changing the encoded sequence.